We're happy to announce the appointment of Lloyd Mackenzie as the company’s President and Chief Operating Officer.

Mr. Mackenzie is a biotechnology Research and Development executive with over 25 years of experience in drug development, manufacturing and control, quality assurance, clinical development and clinical operations. Mr. Mackenzie was formerly the Chief Operating Officer at Nervgen Pharma, with prior executive-level experience at Notable Labs and Aquinox Pharmaceuticals.

“The addition of Lloyd’s leadership, strategic insight and operational experience in all aspects of therapeutic development is a critical step in the development of Symvivo, enabling us to drive our therapeutic programs deeper in the clinic while broadening the application of the bacTRL gene delivery platform,” said Alexander Graves, Chief Executive Officer of Symvivo Corporation. “We’re delighted to have him join the Symvivo team.”

Canadian Media:

Chantal Allan
Sam Brown Inc.
Healthcare Communications

T: 613-319-4384 (CAN)
T: 805-242-3080 (U.S.)
E: chantalallan@sambrown.com